Valproic Acid Induces CYP3A4 and MDR1 Gene Expression by Activation of Constitutive Androstane Receptor and Pregnane X Receptor Pathways
- 28 March 2007
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 35 (7), 1032-1041
- https://doi.org/10.1124/dmd.106.014456
Abstract
In our study, we tested the hypothesis whether valproic acid (VPA) in therapeutic concentrations has potential to affect expression of CYP3A4 and MDR1 via constitutive androstane receptor (CAR) and pregnane X receptor (PXR) pathways. Interaction of VPA with CAR and PXR nuclear receptors was studied using luciferase reporter assays, real-time reverse transcriptase polymerase chain reaction (RT-PCR), electrophoretic mobility shift assay (EMSA), and analysis of CYP3A4 catalytic activity. Using transient transfection reporter assays in HepG2 cells, VPA was recognized to activate CYP3A4 promoter via CAR and PXR pathways. By contrast, a significant effect of VPA on MDR1 promoter activation was observed only in CAR-cotransfected HepG2 cells. These data well correlated with up-regulation of CYP3A4 and MDR1 mRNAs analyzed by real-time RT-PCR in cells transfected with expression vectors encoding CAR or PXR and treated with VPA. In addition, VPA significantly up-regulated CYP3A4 mRNA in primary hepatocytes and augmented the effect of rifampicin. EMSA experiments showed VPA-mediated augmentation of CAR/retinoid X receptor α heterodimer binding to direct repeat 3 (DR3) and DR4 responsive elements of CYP3A4 and MDR1 genes, respectively. Finally, analysis of specific CYP3A4 catalytic activity revealed its significant increase in VPA-treated LS174T cells transfected with PXR. In conclusion, we provide novel insight into the mechanism by which VPA affects gene expression of CYP3A4 and MDR1 genes. Our results demonstrate that VPA has potential to up-regulate CYP3A4 and MDR1 through direct activation of CAR and/or PXR pathways. Furthermore, we suggest that VPA synergistically augments the effect of rifampicin in transactivation of CYP3A4 in primary human hepatocytes.Keywords
This publication has 48 references indexed in Scilit:
- Linear Relationship of Valproate Serum Concentration to Response and Optimal Serum Levels for Acute ManiaAmerican Journal of Psychiatry, 2006
- Antimalarial Artemisinin Drugs Induce Cytochrome P450 and MDR1 Expression by Activation of Xenosensors Pregnane X Receptor and Constitutive Androstane ReceptorPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2005
- Microarray analysis of rat brain gene expression after chronic administration of sodium valproateBrain Research Bulletin, 2005
- Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studiesMedicinal Research Reviews, 2005
- A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expressionBiological Chemistry, 2005
- Pilot Comparison of Extended-Release and Standard Preparations of Divalproex Sodium in Patients With Bipolar and Schizoaffective DisordersAmerican Journal of Psychiatry, 2003
- Valproate and Valproate-Analogues: Potent Tools to Fight Against CancerCurrent Medicinal Chemistry, 2002
- The Mood‐Stabilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinase‐3Journal of Neurochemistry, 2000
- Identification of a human nuclear receptor defines a new signaling pathway for CYP 3 A inductionProceedings of the National Academy of Sciences, 1998
- Valproic AcidDrugs, 1994